Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 40Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 5Pheochromocytoma 4Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoid Tumor 2Stomach Neoplasms 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Medulloblastoma 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × lutetium Lu 177 dotatate × NET × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡